GlassScriptPhysician profile
Prasanti Tatini
NPI 1942403183
$14,378.35
in general payments reported to CMS, 2019-2025
31 companies · $3,074 in 2025
The $3,074 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $1,193 · 2021: $2,722 · 2022: $1,425 · 2023: $2,415 · 2024: $2,997 · 2025: $3,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,442 · Education: $44.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,441.75 |
| Education | $44.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,992.48 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,661.39 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,512.44 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,288.71 | 2020-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $843.90 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $833.93 | 2019-2025 | Rexulti |
| Alkermes, INC. | $777.52 | 2022-2025 | Lybalvi, Aristada |
| Almatica Pharma LLC | $703.02 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Teva Pharmaceuticals USA, INC. | $698.19 | 2019-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $464.75 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $423.45 | 2019-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $357.81 | 2022-2024 | Jornay Pm |
| Neos Therapeutics, LP | $349.79 | 2021-2025 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $330.80 | 2023-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $313.18 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $257.93 | 2022-2024 | Azstarys, Azstarys |
| Eisai INC. | $250.58 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $248.63 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $242.58 | 2024-2025 | Cobenfy |
| Allergan, INC. | $216.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $213.65 | 2020-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $110.97 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $82.42 | 2022-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $46.26 | 2019-2020 | |
| Tris Pharma INC | $35.20 | 2023 | Dyanavel Xr |
| Bausch Health US, LLC | $24.08 | 2021 | |
| Aytu Biopharma, INC. | $21.30 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.11 | 2019 | |
| Owp Pharmaceuticals, INC. | $20.41 | 2021 | |
| Noven Therapeutics, LLC | $18.82 | 2024 | Xelstrym, Secuado |
| Shire North American Group INC | $16.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasanti Tatini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.